Australian Healthcare Innovation: Experts Reveal Top Stocks and Emerging Technologies
Australia’s healthcare sector is buzzing with innovation, from groundbreaking treatments for autoimmune diseases and game-changing cancer therapies to continuous advancements in radiopharmaceuticals. While the scientific breakthroughs are exciting, the ability to translate these into commercially viable products is equally crucial for investors. Recent significant deals, such as Dimerix’s $1.4 billion in future sales for its kidney disease drug and Recce Pharmaceuticals’ research agreement with the US Army for an infected burn wound treatment, highlight the commercial potential within this dynamic industry. These developments offer a timely reminder to investors that despite the performance of established giants like CSL, numerous opportunities exist in the burgeoning healthcare landscape.
However, navigating the world of biotechnology requires a discerning eye. Understanding the complex science behind these innovations can be a challenge for those outside the medical field. To shed light on promising companies and emerging technologies, we spoke with two industry experts: Dr. Charlie Williams from HB Biotechnology and Dr. Melissa Benson from Barrenjoey Capital Partners. They shared their insights on which companies to watch, particularly those with upcoming catalysts, and the innovations that have them most enthused.
Expert Picks: Companies to Watch
Both Dr. Williams and Dr. Benson identified several ASX-listed companies poised for significant developments in the coming months. Their selections focus on companies with strong scientific backing, clear development pathways, and attractive risk-reward profiles.
Dr. Charles Williams’ Top Selections:
Dr. Williams prioritises companies with a clear catalyst on the horizon within the next six to twelve months, those he perceives as undervalued, and offering a favourable risk-reward balance.
Syntara (ASX: SNT)
Syntara is a clinical-stage drug development company focused on therapies for extracellular matrix dysfunction, a condition implicated in chronic and inflammatory illnesses like cancer and fibrosis. Williams notes that the company experienced a significant sell-off after encountering hurdles in progressing from Phase 1 to Phase 3 trials. He believes Syntara is now well-positioned for its Phase 2 trial, with multiple avenues for funding and positive engagement from the FDA.
“They have results coming out for myelodysplastic syndrome, and this is an underappreciated catalyst for the company,” Williams stated, adding that there’s more to like in their pipeline and potential for upside.Telix Pharmaceuticals (ASX: TLX)
Telix Pharmaceuticals, a player in the radiopharmaceuticals space, has faced challenges over the past year, including three FDA rejections and an ongoing SEC investigation. Williams views the current year as an opportunity for Telix to “clear events” and “rebuild investor confidence.”
He suggests that, “you can easily look at the share price and see that you’re acquiring the base operating business at a discount, with some optionality for the future.”Clarity Pharmaceuticals (ASX: CU6)
Clarity Pharmaceuticals, a competitor to Telix in the radiopharmaceuticals sector, is also on Dr. Williams’ radar for an exciting year of upcoming catalysts.
“Clarity will be presenting the results of their Co-PSMA standard of care trial for prostate cancer in the next few months. They should also have results from an imaging study this year. We also anticipate results from their cohort expansion trial for treating pre-chemotherapy patients with prostate cancer,” Williams elaborated.
Dr. Melissa Benson’s Top Selections:
Dr. Benson shares Dr. Williams’ optimism for the radiopharmaceuticals sector and also highlights Telix and Clarity. Additionally, she has identified three companies with major clinical trials underway that warrant close attention.
Immutep (ASX: IMM)
Immutep is dedicated to developing immunotherapy treatments for cancer and autoimmune diseases. The company is a pioneer in therapeutics that leverage Lymphocyte Activation Gene-3 (LAG-3), a critical regulator of the immune system.
Benson emphasised Immutep’s significant lung cancer trial, TACTI-004, progressing this year.
“The premise of Immutep’s drug, Efti, is to boost the immune system to work alongside existing blockbuster cancer drugs, such as Keytruda, to expand the number of patients that see benefit, and also improve survival/durability of treatment. The TACTI-004 trial is the big make or break point for Immutep,” she explained, noting that the data thus far has been “consistent and compelling.”
“There is a significant valuation mismatch given the opportunity in front of IMM,” she added.Clinuvel (ASX: CUV)
Clinuvel focuses on developing treatments for patients with genetic, metabolic, systemic, and life-threatening acute disorders. They hold the sole approved treatment, SCENESSE, for erythropoietic protoporphyria, a rare inherited disease. The company is also investigating SCENESSE for other conditions, including vitiligo, a skin pigmentation disorder, with a crucial Phase 3 trial readout expected.
“All of the prior trial data has been very supportive of SCENESSE’s ability to help re-pigment vitiligo patients – the big data readout in the second half of this year will be important validation of that,” Benson stated.
“It’s been a long time coming for Clinuvel. We don’t think the market has appreciated how important this trial and opportunity is.”Neuren (ASX: NEU)
Neuren is developing novel therapies for debilitating neurodevelopmental disorders that manifest in early childhood. The company has experienced a challenging six months, impacted by a broader market sell-off.
Benson pointed out that Neuren’s second-generation drug, NNZ-2591, is currently in its first late-stage Phase III trial, with more expected later this year. This drug is anticipated to build upon the success of their initial product, DAYBUE.
“A key attribute of Neuren’s is that it can apply a single drug to multiple rare diseases – that is very uncommon. That is valuable commercially, as you not only get the benefits of selling into a rare disease market (high pricing, limited competition, market exclusivity benefits), but you get to repeat this across several diseases, with significant leverage,” Benson explained.
Innovations Capturing Expert Attention
The pace of medical advancement globally is remarkable, making it noteworthy when specific innovations truly capture the attention of seasoned experts.
Dr. Benson reiterated her strong interest in radiopharmaceuticals, noting that while approved products exist, a pipeline of trials is set to define the future trajectory of the market. She specifically highlighted the ongoing trials for Clarity and Telix.
“I’m excited to see if Novartis’ (NYSE: NVS) PLUVICTO is able to expand its reach into a new prostate cancer setting (hormone sensitive) in the form of FDA approval later this year. This would effectively double the market size for PSMA-targeted radioligand therapy (which has positive implications for Telix and Clarity),” Benson added.
She is also closely monitoring Bristol Myers Squibb’s (NYSE: BMY) study into neuroendocrine tumours, which represents a significant test for a highly anticipated alpha-emitter therapy.
Dr. Williams, however, cautioned that enthusiasm for a technology doesn’t always translate into commercial success, citing past experiences with technologies like CRISPR gene editing. He is particularly interested in bispecific antibodies and CAR T-cell therapies, which are showing promise in immunology and cancer treatment, with a focus on the broader market potential in autoimmune diseases.
“There were great results using CAR T-cells targeting lupus with 100% remission rates in patients with severe lupus a few years ago, but it has been difficult to replicate,” Williams observed.
Another innovation he champions, and has personally invested in, is the use of protein degradation as a therapeutic modality.
“In protein degradation, you utilise the body’s own protein clean-up system to mark a disease-causing protein and attract the body’s ubiquitin proteasome system (the protein clean-up system) to turn it back into amino acids and recycle it into the body,” Williams explained. He is currently focused on two key approaches within this field: PROTACs and molecular glue degraders.
A Significant Year Ahead for Healthcare
The healthcare sector is undoubtedly entering a pivotal period. As larger pharmaceutical companies face patent cliffs in the coming years, they are actively pursuing mergers and acquisitions while simultaneously driving their own internal innovations. However, the real excitement may lie with the smaller players.
Bruce Booth of Atlas Venture highlighted in his 2025 Year in Review that approximately 75% to 85% of new FDA drug approvals originate from small, emerging biotechnology companies.
“Small to mid-cap biotechs, private or listed, play a critical role in this ecosystem to get new drugs approved from both a health perspective, along with a revenue perspective,” Williams affirmed.
Australia continues to be a fertile ground for innovative companies, but investors must remain mindful of the commercial viability of these advancements.
